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Abstract
Background: These studies investigate the role of mitoKATP channels, protein kinase C (PKC)
and Mitogen activated protein kinase (p38MAPK) on the cardioprotection of ischemic (IP) and
pharmacological preconditioning (PP) of the human myocardium and their sequence of activation.
Results:  Right atrial appendages from patients undergoing elective cardiac surgery were
equilibrated for 30 min and then subjected to 90 min of simulated ischemia followed by 120 min
reoxygenation. At the end of each protocol creatinine kinase leakage (CK U/g wet wt) and the
reduction of MTT to formazan dye (mM/g wet wt) were measured. Similar protection was obtained
with α 1 agonist phenylephrine, adenosine and IP and their combination did not afford additional
cardioprotection. Blockade of mitoKATP channels with 5-hydroxydecanoate, PKC with
chelerythrine, or p38MAPK with SB203580 abolished the protection of IP and of PP. In additional
studies, the stimulation of mitoKATP channels with diazoxide or activation of PKC with PMA or
p38MAPK with anisomycin induced identical protection to that of IP and PP. The protection
induced by diazoxide was abolished by blockade of PKC and by blockade of p38MAPK.
Furthermore, the protection induced by PMA was abolished by SB203580 but not by 5-
hydroxydecanoate, whereas the protection induced by anisomycin was unaffected by either 5-
hydroxydecanoate or chelerythrine.
Conclusions: Opening of mitoKATP channels and activation of PKC and p38MAPK are obligatory
steps in the signal transduction cascade of IP and PP of the human myocardium with PKC activation
being downstream of the opening of mitoKATP channels and upstream of p38MAPK activation.
Background
Ischemic preconditioning (IP) is a powerful protective en-
dogenous adaptive response of the heart against a pro-
longed ischemic insult. [1,2] However, the application of
IP requires a physical cut of the blood supply which can
be difficult or impractical in many clinical situations. A
way to circumvent these potential problems associated
with the clinical application of IP may be preconditioning
by pharmacological (PP) means or manipulation of the
signalling pathway involved in the protection. A number
of membrane receptors are involved in the phenomenon
of IP including α 1[3–5] and β -adrenoceptors, [6] opioid
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[7] and adenosine A1 and A3 receptors. [8,9] Other factors
such as heat shock proteins, [10] bradykinin, [11] calcium
[12] and nitric oxide synthase activity [13] have also been
shown to participate in the protection of IP, however,
whether the various forms of PP share the same molecular
mechanism with IP is not fully elucidated.
The intracellular sequence of events that translate the
binding of the various agonists to their membrane recep-
tors into the protection of preconditioning remains under
intense investigation. It has been reported that α 1-adren-
oceptors are coupled with protein kinase C (PKC) through
phospholipase activity, [14] that in turn activate p38 Mi-
togen Activated Protein Kinase (p38MAPK) in some cardi-
ac preparations. [15] ATP sensitive potassium channels
have also been implicated in the signal transduction
mechanism of IP, [16,17] and recent evidence from sever-
al investigators [18–20] including ourselves [21] has
shown that the mitochondrial and not the sarcolemmal
KATP channels are involved. The order of involvement of
the above mediators remains controversial although re-
cently it has been suggested that mitochondrial KATP
channels are the triggers in the signal transduction mech-
anism rather than the end effectors. [18]
The aims of the present series of studies were to investigate
the efficacy of pharmacological preconditioning of the
human myocardium with α 1-adrenoceptor and adenos-
ine receptor agonists as compared to ischemic precondi-
tioning and to elucidate the contribution and sequence of
activation of PKC, p38MAPK and mitoKATP channels.
Results
All samples entering the studies completed the applied
protocol and were included in the analysis.
Ischemic versus pharmacological preconditioning (Study 1)
Figures 4A and 4B demonstrate that SI/R alone resulted in
a significant increase in CK leakage and decrease in MTT
reduction when compared to the aerobic controls. They
also show that PP with phenylephrine or adenosine ad-
ministered prior to SI/R is as protective as IP and that their
use in combination does not result in additive protection.
Role of PKC, p38MAPK and mitoKATP channels in IP and 
PP (Study 2)
Figures 5A and 5B show that both IP and PP with phenyle-
phrine or adenosine are equally abolished by the PKC an-
tagonist chelerythrine, the p38MAPK inhibitor SB203580
or the mitoKATP blocker 5-hydroxydecanoate suggesting
that these steps are necessary in the signal transduction
cascade of preconditioning.
Sequence of activation of PKC, p38MAPK and mitoKATP 
channels (Study 3)
The results on CK leakage and MTT reduction shown in
Figures 6A and 6B demonstrate that identical protection is
obtained with the mitoKATP channel opener diazoxide,
the PKC activator PMA and the p38MAPK activator ani-
somycin. Importantly, they also show that whilst the pro-
tection of diazoxide is abolished by the PKC antagonist
chelerythrine and the p38MAPK antagonist SB203580,
the protective effect of PMA is abolished by SB203580 but
not by the mitoKATP channel blocker 5-hydroxyde-
canoate, and the protective action of anisomycin is unaf-
fected by chelerythrine and 5-hydroxydecanoate.
Discussion
The present studies have demonstrated that protection
with PP by activation of α 1-adrenoreceptors or adenosine
receptors is identical to that of IP in the human myocar-
dium. In addition, they have shown that mitoKATP chan-
nels, PKC and p38MAPK are an integral part of the cellular
signal transduction involved in this cardioprotection in
which mitoKATP channels are placed upstream and
p38MAPK placed downstream of PKC. These studies pro-
vide novel information to understand the underlying
mechanism of protection by preconditioning of the hu-
man myocardium and the results have obvious clinical
importance that warrants further discussion.
Pharmacological versus ischemic preconditioning
The demonstration that activation of α 1-adrenoreceptors
with phenylephrine is as protective as IP of the human
myocardium in these studies is supported by other results
in the rat heart [3,5] but contrast with the results reported
by Cleveland et al [4] in the human myocardium. The dif-
fering results may be due to the use of 50 µM phenyle-
phrine by Cleveland et al, [4] a concentration 500 times
the one used in our studies. Using an identical prepara-
tion, we have recently shown [22] that phenylephrine ex-
erts maximal protection at 0.1 µM and that protection is
lost at concentrations ≥  10 µM. It should also be pointed
out that the human trabeculae preparation used by Cleve-
land et al [4] differed from our preparation in that mus-
cles were electrically stimulated and subjected to only 45
min of simulated ischemia which may be another poten-
tial explanation.
The protection induced by adenosine was also identical to
that of IP and the use of the two in combination did not
result in additional benefit up and above that seen with
each intervention alone. These results in the human myo-
cardium are supported by studies in other animal species
[23] but contrast with the results reported by Leesar et al
[24] in the vivo human heart and by McCully et al [25] in
the isolated rabbit heart. In the study by Leesar et al [24]
patients undergoing percutaneous transluminal coronaryBMC Physiology 2002, 2 http://www.biomedcentral.com/1472-6793/2/10
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angioplasty were subjected to three 2-minute balloon in-
flations 5 minutes apart. Under these conditions the ad-
ministration of adenosine was more effective in limiting
ST-segment shift than the balloon inflation protocol. Al-
though we have previously shown [2] that 4 to 5 min of
ischemia are sufficient to precondition the human myo-
cardium, independent of whether this time is attained
with one or two cycles of ischemia, it is conceivable that
in their study [24] the balloon inflation protocol may not
have been sufficient to induce enough ischemia to trigger
preconditioning. This is a strong possibility under clinical
conditions where collateral flow may lessen the severity of
ischemia. Furthermore, in that study [24] changes in ST-
segment, that are modulated by sarcolemmal KATP chan-
nels, [26] were used as the main end-point and it is now
recognized that the protection of preconditioning may be
Figure 1
Protocol for Study 1 to investigate the efficacy of preconditioning via α 1-adrenoceptors or adenosine (A) receptors alone and
in combination with IP (n = 6 specimens/group): (i) time-matched aerobic control, (ii) SI/R alone, (iii) IP induced with 5 min of
SI/ 5 min R before SI, (iv) phenylephrine (P) for 5 min and 5 min washout (W) before SI, (v) adenosine (A) for 5 min and 5 min
washout (W) before SI, (vi) phenylephrine (P) for 5 min and 5 min washout (W) before IP, (vii) adenosine (A) for 5 min and 5
min washout (W) before IP and (viii) adenosine (A) for 5 min and 5 min washout (W) followed by phenylephrine (P) for 5 min
and 5 min washout (W) prior to SI.
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Figure 2
Protocol for Study 2 to investigate the role of PKC, p38MAPK and mitoKATP channels in the cardioprotective effect of IP and
PP with phenylephrine (P) or adenosine (A) (n = 6 specimens/group): (i) time-matched aerobic control, (ii) SI/R alone, (iii) IP
alone prior to SI, (iv) chelerythrine (CHE) for 10 min prior to IP, (v) SB203580 (SB) for 10 min prior to IP, (vi) 5-hydroxyde-
canoate (5-HD) for 10 min prior to IP, (vii) phenylephrine (P) for 5 min and 5 min washout (W) before SI, (viii) chelerythrine
(CHE) for 10 min prior to phenylephrine (P) for 5 min and 5 min washout (W), (ix) SB203580 (SB) for 10 min prior to phenyle-
phrine (P) for 5 min and 5 min washout (W), (x) 5-hydroxydecanoate (5-HD) for 10 min prior to phenylephrine (P) for 5 min
and 5 min washout (W), (xi) adenosine (A) for 5 min and 5 min washout (W) before SI, (xii) chelerythrine (CHE) for 10 min
prior to adenosine (A) for 5 min and 5 min washout (W), (xiii) SB203580 (SB) for 10 min prior to adenosine (A) for 5 min and
5 min washout (W) and (xiv) 5-hydroxydecanoate (5-HD) for 10 min prior to adenosine (A) for 5 min and 5 min washout (W).
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Figure 3
Study 3 protocol designed to elucidate the sequence of the participation of involvement of mitoKATP channels, PKC and
p38MAPK in the signal transduction cascade of cardioprotection. For this purpose, in addition to the (i) aerobic time-matched
control and (ii) SI/R alone the following groups were studied (n = 6 specimens/group): (iii) diazoxide alone for 10 min prior to
SI, (iv) chelerythrine (CHE) for 20 min with diazoxide added for the last 10 min prior to SI, (v) SB203580 (SB) for 20 min with
diazoxide added for the last 10 min prior to SI, (vi) PMA alone for 10 min prior to SI, (vii) SB203580 (SB) for 20 min with PMA
added for the last 10 min before SI, (viii) 5-hydroxydecanoate (5-HD) for 20 min with PMA added in the last 10 min before SI,
(ix) anisomycin (ANS) alone for 10 min prior to SI, (x) chelerythrine (CHE) for 20 min with anisomycin (ANS) added for the
last 10 min prior to SI and (xi) 5-hydroxydecanoate (5-HD) for 20 min with anisomycin (ANS) added for the last 10 min prior
to SI.
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mediated by mitochondrial rather than by sarcolemmal
KATP channels. [18–21] The results reported by McCully et
al [25] that adenosine is more potent than and extends the
cardioprotection of IP in the rabbit heart are difficult to
explain because they used a protocol of 5 min ischemia/5
min reperfusion for preconditioning which is identical to
the one used in our studies and shown to afford optimal
protection in other preparations. [5,9] However, since ad-
enosine and IP use identical cellular signal transduction
mechanism to induce protection, the most likely explana-
tion of their results may be the presence of some un-
known factor that may have influenced the severity of the
IP insult and therefore its protective efficacy.
Mechanism of preconditioning
The elucidation of the factors involved in the signal trans-
duction pathway of preconditioning has been the subject
of intense investigation and although the participation of
factors such as PKC [17,19,27] and mitoKATP channels
[16–21] is well established, their relevance and the se-
quence of activation remains controversial. The present
studies are the first to demonstrate that PP and IP of the
human myocardium share identical signal transduction
cascade that involves mitoKATP channels, PKC and
p38MAPK in that order. Wang et al [28] showed that PKC
inhibition with chelerythrine or calphostin C completely
abolished the beneficial effects of diazoxide in the isolat-
ed rat heart, thus providing further support that mitoKATP
channels are upstream of PKC. However, Pain et al [18]
and Miura et al [29] using chelerythrine and calphostin C
to block PKC were unable to confirm this observation in
the rabbit, suggesting that these differences could arise as
a result of different animal species. In spite of this, it is in-
teresting to note that Pain et al [18] reported that genis-
tein, a tyrosine kinase antagonist, blocked the protection
induced by diazoxide which indicates that activation of
kinases also lies downstream of mitoKATP channels in the
rabbit heart.
Our demonstration that activation of any one of the com-
ponents of the transduction cascade investigated in our
studies (mitoKATP channels, PKC, p38MAPK) can provide
identical protection and that blockade of any of them in-
dividually completely abolishes protection indicates that
in the human myocardium there is only one pathway of
protection by preconditioning. The failure to obtain addi-
tional protection when more than one agent was used to
induce PP or when these agents were used in combination
with IP further support this thesis. But again, the mecha-
nism of preconditioning the human myocardium may
not be applicable to all species as suggested by the need to
combine the inhibition of PKC and tyrosine kinase to
abort the protection of preconditioning in pigs. [30]
The molecular interactions between the various compo-
nents of the preconditioning pathway are not well under-
stood. There is evidence that mitoKATP channel opening
increases radical oxygen species production which in turn
may activate PKC, [18] but it is well known that mitoKATP
channels are also modulated by PKC [19]. The above and
the realization of selective translocation of PKC with pre-
conditioning, [27,28,31] suggest that PKC may play a
dual role upstream and downstream of mitoKATP chan-
nels. Our observation that blockade of PKC abolishes the
protection by diazoxide does not eliminate that possibili-
ty.
Our results have shown that activation of p38MAPK is a
crucial step in the transduction pathway of precondition-
ing in the human myocardium. Activation of p38MAPK
has also been connected to preconditioning in the rabbit
heart, [32] however the relationship could not be estab-
lished in rat [33] and pig [34] hearts. Therefore, it seems
that once more the components of the signal transduction
pathway of preconditioning are species-dependent.
It is still unknown whether the activation of p38MAPK is
the last step of the transduction cascade that phosphor-
ylates the end-effector and whether there is a simple or
multiple effectors and their location. p38MAPK can phos-
phorylate a wide range of proteins, some of which may be
potential candidates for end-effectors of preconditioning.
Thus, for example, the low molecular weight heat shock
protein HSP27 may be phosphorylated by p38MAPK via
the intermediate MAPKAPK2 [35] and this may lead to
polymerization of actin [36] and to increase tolerance of
the cytoskeleton to stress. [37] Translocation of PKC iso-
forms to mitochondrial sites, intercalated discs and nucle-
us may suggest that p38MAPK activation in these places
may activate enzymes involved with energy production,
intercellular communication through cell junctions or
gene transcriptions.
Our results suggest that mitoKATP channels are not the
end-effectors of cardioprotection by preconditioning of
the human myocardium. The concept that mitoKATP
channels may be the end-effectors of preconditioning has
been based on the efficacy of diazoxide, a highly selective
mitoKATP channel opener, to mimic cardioprotection by
preconditioning [20,21] and the blockade of this protec-
tion by 5-hydroxydecanoate, [20,21] a specific mitoKATP
channel blocker; however, it was never clear whether the
actions of these channels were limited to the mitochon-
dria or were part of a more complex signal transduction
cascade with effects on other cellular structures. The effect
of opening the mitoKATP channels remains controversial
and whereas some investigators have reported large de-
creases in mitochondrial membrane potential affecting
respiration and resulting in a reduction in Ca2+ uptakeBMC Physiology 2002, 2 http://www.biomedcentral.com/1472-6793/2/10
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into mitochondria, [38] others have observed little effect
on membrane potential, bioenergetics or Ca2+ uptake but
important changes on matrix and inter-membrane space
volumes. [39] The reason given for these discrepancies
was the use of high doses of mitoKATP channel openers in
the former studies [39] but this does not clarify how
changes in mitochondrial volume are connected to PKC
activation, that is downstream in the signal transduction
cascade.
The diagram in Figure 7 describes our proposal of the sig-
nal transduction cascade of preconditioning in the human
myocardium. It is suggested that upon activation of sarco-
lemmal receptors (e.g. adenosine receptors, α 1-adrenore-
ceptors) mitoKATP channels are opened via Gi proteins
and PKC, possibly PKC-δ  [28]. The opening of mitoKATP
channels will activate PKC possibly via the production of
radical oxygen species [18]. PKC may then translocate to
various cellular sites including the mitochondria, sarco-
lemma and intercalated discs, and nucleus, a phenomena
that may involve specific PKC isoforms, where p38MAPK
will be activated. In turn, p38MAPK may activate a simple
or multiple end-effectors directly or via MAPK intermedi-
ates. It is clear that more studies are required to fully elu-
cidate the signal transduction pathway of preconditioning
and the coupling between its components.
Clinical implications
The findings that the cardioprotection achieved by activa-
tion of α 1-adrenoreceptors or adenosine receptors is as
potent as the one obtained with IP and that their use in
combination does not result in additional benefit have
obvious major clinical implications because maximal pro-
tection can be attained without the need to occlude the
coronary arteries to induce ischemia. The procurement of
cardioprotection with stimuli of receptors as diverse as α 1-
adrenoreceptors and adenosine receptors can be clinically
advantageous because some of these agents may be con-
traindicated in certain conditions (e.g. α 1-adrenoreceptor
agonists in hypertension, adenosine in the presence of al-
terations of the cardiac conduction system). These inter-
ventions can be useful to combat ischemic injury in
different clinical conditions such as coronary angioplasty,
cardiac surgery and heart transplantation; however, it is
necessary to mention that our studies were performed in
an in-vitro preparation and therefore any extrapolation to
the clinical setting should be made with caution.
The realization that cardioprotection by PP and IP of the
human myocardium is mediated by one obligatory signal
transduction pathway also opens the therapeutical win-
dow for direct manipulation of its components. Recently,
we have demonstrated that although the myocardium
from patients with poor left ventricular function (ejection
fraction < 30%) or with diabetes cannot be protected with
IP, the mitoKATP channel opener diazoxide elicited pro-
tection in the former but not in the latter [40]. This sug-
gests that if part of the signal transduction cascade is
affected by disease states, cardioprotection can still be ob-
tained by bypassing the defective components. It is also of
clinical relevance that blockade at any stage of the signal
transduction involved in preconditioning does not seem
to exacerbate injury suggesting that this pathway is solely
used for cardioprotection and not in tissue injury.
Possible limitations of the study
A potential limitation of our studies was the use of atrial
tissue as opposed to ventricular myocardium and the fact
that this was a necrosis in vitro model, and therefore any
extrapolation must be conducted with caution. Another
limitation might be that right atrial appendages were ob-
tained from patients subjected to various medical treat-
ments such as nitrates and beta blockers, which may have
influenced the simulated ischemia/reoxygenation injury
and the protection induced by preconditioning. However
this effect is unlikely to be significant as all the specimens
responded similarly to ischemic injury and precondition-
ing.
Conclusions
The current studies demonstrate that protection with
pharmacological preconditioning by activation of α 1-
adrenoreceptors or adenosine receptors is identical to that
of ischemic preconditioning in the human myocardium.
In addition, they show that mitoKATP channels, PKC and
p38MAPK are an integral part of the cellular signal trans-
duction involved in this cardioprotection in which mi-
toKATP channels are placed upstream and p38MAPK
placed downstream of PKC.
Materials and methods
Experimental preparation
Experiments were performed on trabeculae obtained from
the right atrial appendage of patients undergoing elective
coronary artery bypass graft surgery or aortic valve replace-
ment in a cell necrosis model that was developed and
characterised in our laboratory and that has been de-
scribed previously [41]. The investigation conforms with
the principles outlined in the Decleration of Helsinki. Do-
nor patients were excluded if they had enlarged atriums,
atrial arrhythmias, poor left ventricular function (ejection
fraction <30%), right ventricular failure or were taking
oral hypoglycaemic agents, opioid analgesia, KATP chan-
nel openers or catecholamines. Local ethical committee
approval was obtained for the harvesting technique. Tem-
perature was maintained at 37°C throughout the experi-
ments and simulated ischemia was induced by bubbling
the medium with 95% N2/5% CO2 (pH 6.8–7.0) instead
of 95% O2/5% CO2 (pH 7.36 and 7.45) and replacing D-
glucose with 2-deoxy-D-glucose.BMC Physiology 2002, 2 http://www.biomedcentral.com/1472-6793/2/10
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Figure 4
Creatine Kinase (CK) leakage into the media (A) during the 120 min reoxygenation period and MTT reduction by the slices (B)
at the end of the reoxygenation period in human atrial myocardium subjected to various protocols (see Figure 1) to investigate
the efficacy of preconditioning via α 1-adrenoreceptors or adenosine receptors alone and in combination with IP (Study 1).
Data are expressed as mean ± SEM of six experiments. *p < 0.05 vs SI/R alone group.
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Figure 5
Creatine Kinase (CK) leakage into the media (A) during the 120 min reoxygenation period and MTT reduction by the slices (B)
at the end of the reoxygenation period in human atrial myocardium subjected to various protocols (see Figure 2) to investigate
the role of PKC, p38MAPK and mitoKATP channels in ischemic and pharmacological preconditioning with phenylephrine (P) or
adenosine (Study 2). Data are expressed as mean ± SEM of six experiments. *p < 0.05 vs. SI/R alone group. (5-HD: 5-hydrox-
ydecanoate, SB: SB203580).
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Figure 6
Creatine Kinase (CK) leakage into the media (A) during the 120 min reoxygenation period and MTT reduction by the slices (B)
at the end of the reoxygenation period in human atrial myocardium subjected to various protocols (see Figure 3) to investigate
the sequence of activation of the mediators of pharmacological and ischemic preconditioning (Study 3). Data are expressed as
mean ± SEM of six experiments. *p < 0.05 vs SI/R alone group. (CHE: chelerythrine, 5-HD: 5-hydroxydecanoate, SB: SB203580,
PMA: phorbol-12-myristate-13-acetate).
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Solutions and chemicals
The incubation medium was prepared daily with de-ion-
ized distilled water and contained (in mM): NaCl2 (118),
KCl (4.8), NaHCO3 (27.2), MgCl2 (1.2), KH2PO4 (1.0)
CaCl2 (1.25), HEPES (20) and D-glucose (10) or 2-deoxy-
D-glucose (10). All the chemicals were purchased from
Sigma Chemicals.
Experimental time course
All the muscles were equilibrated for a 30 min period be-
fore being randomly assigned to serve as time-matched
aerobic controls or subjected to a 90 min period of simu-
lated ischemia (SI). The muscles were then reoxygenated
(R) for another 120 min by incubation in 10 ml of oxy-
genated medium with added glucose. At the end of the ex-
perimental protocols, samples from the incubation media
used during the reoxygenation period were collected for
the assessment of creative kinase (CK) leakage and the tis-
sue was taken for the assessment of viability (reduction of
3- [4,5-dimethylthiazol-2-yl]-2,5-diphenyltetiazolium
bromide (MTT). All agents tested were added for 5, 10 or
20 min at the end of the equilibration period and before
the induction of SI. The doses of the agent used in the
present studies (phenylephrine at 0.1 µM, adenosine at
100 µM, chelerythrine at10 µM, 5-hydroxydecanoate at 1
mM, SB203580 at 10 µM, PMA at 1 µM diazoxide at 100
µM anisomycin at 1 nM) were selected following prelimi-
nary dose-response studies for each of the drugs.
Figure 7
Proposed schematic representation of the signal transduction mechanism leading to cardioprotection by pharmacological and
ischemic preconditioning of the human myocardium. Upon activation of sarcolemmal receptors mitoKATP channels are opened
via G proteins and possibly PKC-δ . The opening of mitoKATP channels will activate PKC possibly via the production of radical
oxygen species (ROS). PKC may then translocate to various cellular sites including the mitochondria, sarcolemma and interca-
lated discs, and nucleus, a phenomenon that may involve specific PKC isoforms, where p38MAPK will be activated. In turn,
p38MAPK may activate a single or multiple end-effectors directly or via MAPK intermediates. PLC: phospholipase C, PLD:
phospholipase D.
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Study groups
In Study 1, the efficacy of preconditioning via α 1-adreno-
ceptors or adenosine receptors alone and in combination
with IP was investigated following the protocol described
in Figure 1.
Study 2 investigated the role of PKC, p38MAPK and mi-
toKATP channels in the cardioprotective effect of IP and of
PP with phenylephrine and adenosine following the pro-
tocol described in Figure 2.
Study 3 was designed as described in Figure 3 to elucidate
the sequence of the participation of involvement of mi-
toKATP channels, PKC and p38MAPK in the signal trans-
duction cascade of cardioprotection.
In the three studies, n = 6 specimens from different sub-
jects/group were used.
Assessment of tissue injury and viability
Tissue injury was determined by measuring the leakage of
CK into the incubation medium during the 120 min reox-
ygenation period. This was assayed by a kinetic ultraviolet
method based on the formation of NAD (Sigma Cata-
logue No. 1340-K) and the results expressed as U/g wet
wt.
Tissue viability was assessed by the reduction of MTT to a
blue formazan product at the end of the experimental
time. The absorbance of the blue formazan formed was
measured on a plate reader (Benchmark, Bio-Rad Labora-
tories, California, USA) at 550 nm and the results ex-
pressed as mM/g wet wt [41].
Statistical analysis
All data are presented as mean ± SEM. All values were
compared by ANOVA with application of a post hoc Tuk-
ey's test. Statistical significance was taken as p < 0.05.
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